万春医药 BYSI 深 沪
等待开盘 08-20 09:30:00 美东时间
0.7633
+0.045
+6.29%
华盛通- 最 高0.79
- 今 开0.72
- 成交量 11.09万股
- 最 低 0.70
- 昨 收 0.7181
- 总市值 3.14万
- 52周最高 2.44
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 0.6699
- 委 比 20.00%
- 总股本 4.11万
- 历史最高 48.49
- 量 比 0.03
- 振 幅 12.53%
- 历史最低 0.542
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BeyondSpring GAAP EPS of -$0.02
BeyondSpring press release (BYSI): Q2 GAAP EPS of -$0.02. Net loss was $1.8 million for the quarter ended June 30, 2026, compared to $1.9 million for the quarter ended June 30, 2025. Cash, cash equiva...
08-17 16:32
BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.
08-15 05:21
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Shares of Eton Pharmaceuticals Inc (NASDAQ:ETON) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued FY26 revenue guidance above estimates. Eton Pharmaceuticals reported quarterly earnings of 43 cents per share which beat the...
08-14 16:37
BeyondSpring Appoints Min Qiu As CEO, Effective July 1
Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully
06-04 19:10
Beyondspring Announces Updated Efficacy And Safety Data From Its Phase 2 303 Study Evaluating Pembrolizumab Plus Plinabulin And Docetaxel In Patients With Metastatic Non-Small Cell Lung Cancer; Sees Meaningful Clinical Benefit
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors Durable survival benefit:
06-02 19:15
BeyondSpring GAAP EPS of -$0.06
BeyondSpring press release (BYSI): Q1 GAAP EPS of -$0.06. Cash, cash equivalents, and short-term investments were $7.9 million as of March 31, 2026 More on BeyondSpring Historical earnings data for Be...
05-13 19:29
BeyondSpring Q1 EPS $(0.05) Up From $(0.06) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.05) per share. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year.
05-13 19:23
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring Inc. reported financial results for Q1 2026 and highlighted advancements in its pipeline. Plinabulin demonstrated potential as a backbone agent for ADC-based therapies, improving efficacy and tolerability. SEED's ST-01156, a molecular glue degrader, advanced into clinical development. The company's R&D expenses increased slightly, while G&A expenses decreased. Net loss was $2.4 million, and cash reserves were $7.9 million. BeyondSpri...
05-13 11:00
